Hear Frost and Sullivan's industry expert speak at the International Biotech 2003 conference and exhibition in London next week
Within Europe it is very difficult to assess how life sciences funding may change from one year to the next, and how this may affect the many businesses involved.
Annabel Entress, industry analyst of Frost and Sullivan's drug discovery technologies group, will shed some light on the intricate and complex funding system across Europe.
On 26 November at 12:35 p.m., she will be discussing the feasibility study for the forthcoming Frost and Sullivan end user study entitled Life science funding - providing clarity in Europe.
This study is designed to answer the many complex issues surrounding Life science funding in Europe, and how reliable predictions on spending patterns could be made.
If you are interested in this subject and would like to meet Annabel to discuss her research aim, attend her presentation at International Biotech 2003 in Olympia next week.
